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Chromosome instability is a predominant trait of
fibroblasts from Li-Fraumeni families
JM Boyle1, ELD Mitchell1, MJ Greaves1, SA Roberts2, K Tricker3, E Burt1, JM Varley1, JM Birch3 and D Scott1
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Summary Previous work has indicated a role for p53 in cell cycle control, genomic stability and cellular responses to DNA-damaging agents.
However, few data are available for human fibroblasts heterozygous for defined germline mutations in TP53. We report studies on 25 strains
derived from 12 families with Li-Fraumeni syndrome (LFS) and 18 strains from normal volunteers. The families include three that are classical
LFS families, but in whom no TP53 mutation has been found. In the families with mutations, increased longevity and resistance to low-dose-
rate ionizing radiation showed a statistically significant association with the presence of TP53 mutations. However, not all heterozygotes had
increased longevity or were radioresistant, and fibroblasts from cancer-affected members of LFS families without TP53 mutations showed no
significant increase in either of these end points. In contrast, all mutation-carrying strains showed evidence of genomic instability, expressed
as aneuploidy, and accumulated structural chromosome aberrations in up to 100% of cells, usually accompanied by loss of the wild-type TP53
allele, immediately before senescence. Levels of aneuploidy higher than in normal cells were also observed in fibroblasts from families
without TP53 mutations, suggesting that chromosome instability is a major factor in determining the cancer proneness of these families.
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The tumour-suppressor gene TP53 encodes a 53-kiloDalton
nuclear phosphoprotein that is commonly found to be mutated in a
wide variety of human tumours. Cells defective in p53 have been
reported to show increased life span, genetic instability and resis-
tance to DNA-damaging agents. However, most of these studies
have used rodent cells (including those from p53 knockout mice),
p53-affected tumour cells that may carry an accumulation ofother
genetic alterations, or normal human cells transfected with mutant
TP53 under vector control.
Germline mutations in TP53 are found in a proportion of fami-
lies predisposed to cancer (Li and Fraumeni, 1969; Malkin et al,
1990; Birch et al, 1994; Varley et al, 1997a and b). Classical
Li-Fraumeni syndrome (LFS) families have a proband with
sarcoma under the age of45 years, a first-degree relative with any
cancer under age 45, and a first- or second-degree relative with
either a sarcoma at any age or any other cancer under age 45 years.
Li-Fraumeni-like (LFL) families conform to a more relaxed
definition (Birch et al, 1994). In both syndromes the predominant
cancers are bone and soft tissue sarcomas and breast cancer, plus
an excess of brain tumours, leukaemia and adrenocortical carci-
nomas diagnosed under age 45 years. An understanding of the
consequences ofthe p53 mutations found in these families, partic-
ularly in the mesenchymal cells, is important for the management
and counselling of patients. Skin fibroblasts provide an accessible
mesenchymal cell type, but to date there have been very few
reported studies involving such cells.
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The initial description of the growth and chromosomal insta-
bility of LFS fibroblasts was reported by Bischoff et al (1990) for
fibroblasts from five families with mutations in codons 133, 175,
184 and 248 (Tainsky et al, 1995). Immortal derivatives of two of
the fibroblast strains have been widely studied (Yin et al, 1992;
Dulic et al, 1994; Ford and Hanawalt, 1995; Rong et al, 1995;
Tsutsui et al, 1995). Cells from three of the families had normal
sensitivity to high-dose-rate (HDR) ionizing radiation (Little et al,
1987), but mutation-carrying fibroblasts from another extensively
studied family with a germline mutation in codon 245 (Srivastava
et al, 1990) were resistant to HDR radiation (Bech-Hansen et al,
1981). The most radioresistant strain (2800T) was derived from a
blood relative ofthe affected proband who did not have the codon
245 mutation, but had acquired a mutation in codon 234 during
growth in vitro (Mirzayans et al, 1995). Recently, we reported that
LFS fibroblasts with TP53 mutations are more resistant than
normal fibroblasts to low-dose-rate (LDR) ionizing radiation
(Sproston et al, 1996).
Largely through the Manchester Children's Tumour Registry,
we are in the advantageous position of being able to acquire
biopsy material from a relatively large group of Li-Fraumeni
families. For the first time, sufficient numbers ofcell strains from
these families and a control group of normal volunteers have been
studied to allow a comprehensive investigation of a number of
relevant end points. To establish a clearer understanding of the
properties conferred by TP53 mutations on human fibroblasts we
have now compared strains from 18 normal individuals with cells
derived from 12 LFS and one LFL families. Cell strains were
established and expanded to senescence, during which time
changes in chromosome constitution and heterozygosity at TP53
were documented and their radiation sensitivity was determined at
early passages. We were particularly interested to know whether
increased longevity, chromosome instability and radiation resis-
tance were confined to cells carrying TP53 mutations, and whether
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Table 1 Properties of cell strains in (A) normal controls and (B) Li-Fraumeni families
A
Strain Age at Sex T. (days)a Max PDb
biopsy (years)
H01ll Embryo M 2.0 63
25MA 49 M NDc 7
83MA 34 F 2.0 36
84MA 26 F 3.3 26
85MA 28 M 3.1 36
86MA 30 M ND 17
89MA 34 F 4.9 24
93MA 19 M 2.9 64
105MA 58 M 3.2 34
120MA 47 F 2.3 33
155MA 35 F 9.3 14
156MA 35 F 4.3 17
157MA 20 F 3.8 9
162MA 27 F 2.6 26
169MA 52 F 5.1 11
170MA 54 F 4.5 17
174MA 56 M 6.4 6
176MA 31 F 4.7 38
B
Strain Familyd Person Type Mutation Age at Therapye Sex TDa Max Sensitivityf
biopsy (years) (days) PDb
FH1 266 11-4 LFS Affected R248W/+ 20 Y M 3.2 55r
163MA 11-2 Affected R248W/+ 31 N F 3.2 70r
Clone
163/29 R248W/- NDcr
66MA 84 IV-3 LFS Unaffected +1+ 19 N F 4.1 28 n
131 MA 222 IV-i LFS Affected R248Q/+ 18 Y (15) M 4.1 23 n
138MA 83 111-4 LFS Unaffected R175H/+ 16 N M 3.3 47r
21MA 111-4 11 N M 3.2 44r
22MA 11-4 Unaffected +/+ 39 N F 3.6 22 ND
136MA I-i Unaffected +/+ 77 N M 3.0 24 n
141MA 1-2 Unaffected +/+ 77 N F 4.0 17 n
135MA 11-2 Affected R175H/+ 48 N M 2.5 74r
110MA 85 IV-i LFLAffected El8OK/+ 18 Y(16) F 3.2 53 r
109MA 111-7 Unaffected El18OK/+ 52 N M 3.2 64 n
124MA 16 IV-i LFS Affected Y220C/+ 13 N F 3.2 27 r
123MA 111-2 Affected +/+ 34 Y (11) M 2.6 14, 20h n
125MA 11-2 Affected +/+ 55 N F 3.0 15 n
160MA 7003 111-6 LFS Affected L344P/+ 45 Y (days) M 3.8 17 ND
161 MA-F Ex tumour L344P/- 19 n
164MA JLFS Affected G245S/+ 47 NK' F 6.4 58 n
172MA k LFS Affected R337C/- 34 N F ND 26 n
2800T ILFS Y234C/+ 71 NK M ND ND r
Polycythemia vera
79MA 81 Ill-S LFS Affected +/+ 70 Y (25) F 3.6 38 n
80MA IV-i Unaffected +/+ 45 N M 3.2 39 r/n
81 MA IV-3 Affected +/+ 40 N F 2.2 55 rOn
126MA 88 11-2 LFS Affected +1+ 29 N M 3.5 53 n/r
130MA I-i Unaffected +/+ 59 N M 3.0 18 n
146MA 80 IV-19 LFSAffected +/+ 65 Y(13) F 6.9 13 n
154MA V-6 Affected +/+ 36 Y (7) F 2.7 35 n
159MA V-i1 Affected +/+ 46 Y(15) F 3.9 19 ND
aMean population doubling times at early passages. bPD, population doubling. cND, not determined. dExcept where indicated, details of family, person, type and
mutation are given in Varley et al. (1997b). ey, yes, N, no, indicates whether or not radio- or chemotherapy was received (number of years) before biopsy.
'Resistance to LDR radiation, being within (n) or more resistant than (r) the normal range at both 3 Gy and 6 Gy, r/n, resistant at 3 Gy and normal at 6 Gy (see
text).gFrom Sproston et al (1996). hTwo determinations. 'NK, not known. iMacGeoch et al (1995). kBarnes et al (1992). 'Bech-Hansen et al (1981).
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any of these end points were expressed in cells from families
without TP53 mutations. Our results demonstrate that chromo-
some instability is a dominant trait, occurring in all mutation-
carrying LFS strains tested, whereas increased longevity and
radioresistance may be secondary events as these features are not
expressed by all strains. Chromosome instability also occurs, but is
less strongly expressed, in cells from cancer-affected members of
LFS families without mutations.
MATERIALS AND METHODS
Establishment of cultures
We have classified cultures according to whether they were
derived from classical Li-Fraumeni syndrome (LFS) or
Li-Fraumeni-like syndrome (LFL) families (see Introduction).
Thereafter, we use the general term Li-Fraumeni (LF) to include
both LFS and LFL strains. Skin biopsies were obtained with
informed consent from cancer-affected patients and their blood
relatives of LF families documented previously (Varley et al,
1997a and b and references in Table 1) and from normal control
individuals including one spouse (strain 22MA) from LFS family
83 (Table 2A). The biopsies were chopped into fragments approx-
imately 1 mm3 and allowed to attach to the surface of a plastic
Petri dish or T30 flask (Costar) for 15 min before addition of
minimal essential medium with Earles' salts and 15% fetal calf
serum (Gibco) (LF medium), which was renewed twice weekly.
Patches of fibroblasts grew from several of the tissue fragments,
and these were trypsinized and seeded into a fresh T30 flask and
incubated until a confluent layer was obtained, which was desig-
nated passage zero (P0).
Longevity study
Early passage cells (generally P,-P4) were thawed from stocks
frozen in liquid nitrogen and each culture was expanded by
repeated subcultures until senescence. At each subculture the cells
were trypsinized and counted using a haemocytometer, then
diluted 1:3 into a fresh flask. Cumulative population doublings
(PD) were calculated from the cell counts at each passage, and the
maximum PD obtained when the cultures senesced was adjusted
by adding the number ofdoublings achieved before the start ofthe
experiment. Cultures were grown without antibiotics and were
regularly monitored for Mycoplasma infection (Chen, 1977),
which was never seen. At intervals, aliquots ofcells were frozen in
95% fetal calf serum plus 5% dimethyl sulphoxide.
Chromosome preparation and analysis
Metaphase preparations were made by standard procedure after an
overnight incubation with 0.1 ,tg ml-l Colcemid (Gibco). The
preparations were stained with 10% Giemsa in pH 6.8 buffer and
scored for chromosome number and structural aberrations (e.g.
dicentrics, ring chromosomes, fragments and marker chromo-
somes).
TP53 status
The allelic status of TP53 was determined by polymerase chain reac-
tion (PCR) amplification ofgenomic DNA using primers for specific
mutation sites whose allelic forms were determined after digestion
with restriction endonucleases that recognize the difference between
normal and mutated sequences (Varley et al, 1997 a and b).
Table 2 Classification of cell strains (A) and analysis of longevity (B)
Normal controls Families with TP53 mutation Families without TP53 mutation
TP53 status +I+ +Im +Im +I+ +I+
Clinical status and family Normal Affected Not Blood Affected Not
relationships affected relative of with LFS- affected
+/m case type blood
cancer relative
of
affected
case
Group designation A B C D E F
Number of strains in group 19 8 3 5 6 2
Strain designations As Table FH1 21 MA 66MA 79MA 80MA
1A plus 11OMA 109MA 123MA 81MA 130MA
22MA 124MA 138MA 125MA 126MA
(see text) 131MA 136MA 146MA
135MA 141 MA 154MA
160MA 159MA
163MA
164MA
B
Rangea 6-64 17-74 44-58 15-28 24-55 18-39
Mean + s.d. 26.3+ 16.6 47.1 + 21.9 51.7+ 10.8 20.8 ± 5.3 37.3+ 14.7 28.5 + 14.8
Mann-Whitney U-test
comparisons with controls 0.031 0.021 0.64 0.11 0.47
aValues are population doublings.
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Figure 1 Cumulative population doublings of (A) normal and (B) Li-Fraumeni fibroblast strains
Table 3 Spearman rank comparison of longevity of fibroblasts with their RESULTS
mean doubling time and age of donor
Comparison Group n r P
Maximum PD Controls (A) 19 -0.49 0.034
vs LF (all) 24 - 0.41 0.045
age at biopsy LF (B + C) 11 + 0.36 0.29
Maximum PD Controls (A) 17 - 0.71 0.001
vs LF (all) 24 - 0.18 0.41
mean doubling time LF (B + C) 11 - 0.52 0.10
n, rand Pare number of samples, Spearman rank correlation coefficient and
significance of the correlation respectively.
Radiation sensitivity
Clonogenic survival after exposure to LDR 6°Co radiation
(0.011 Gy min-') was determined as described (Sproston et al, 1996),
except that test cells were plated in the absence offeeder cells.
Tumorigenicity
Aliquots of 5 x 106 cells in Hanks buffered salts solution were
injected subcutaneously at one site in the flank of each of three 6-
to 8-week-old female nu/nu mice per cell line. The mice were
maintained in aseptic isolators, fed chow and water ad libitum and
examined weekly for tumour growth at the site of injection. Mice
showing no sign of tumour growth after 1 year were humanely
killed. The experiment was performed under UK Home Office
licence.
Statistical analysis
Comparisons between groups of donors were made using non-
parametric Kruskal-Wallis and Mann-Whitney U-tests.
Correlations between parameters were assessed using Spearman
rank correlations. Comparisons of proportions of cell lines with
mutations were performed using x2 or Fisher's exact tests as
appropriate. A significance level of0.05 was used throughout.
0 100 150 200 250
Days
350 400
Longevity
The origins of cultures, their TP53 status, longevity and relative
radiation sensitivities (as detailed below) are summarized in Table
1, together with information on the donors. Examples of the
expansion ofcell strains to senescence are shown in Figure 1.
For comparative purposes, the cell strains were classified
according to their TP53 status, clinical and family relationships
(Table 2A). Group A contains strains from normal volunteers plus
strain 22MA from a normal spouse offamily 83. Group C contains
strains 21MA and 138MA derived from biopsies obtained 5 years
apartfrom the same donor. Group D, bloodrelatives oftheheterozy-
gous probands, contains strains from cancer-affected (123MA,
125MA) and -unaffected (66MA, 136MA, 141MA) relatives.
First, we used the Kruskal-Wallis test to demonstrate significant
differences between groups A to F (P = 0.034). In a Mann-
Whitney U-test, the longevity of LF strains taken as a group
(groups B to F combined) was significantly greater (P = 0.029)
than that ofthe normal controls (group A). The longevity of TP53
mutation-carrying strains (groups B + C combined) was even more
significantly different (P = 0.005) than that ofthe control group A.
Using Mann-Whitney tests to compare individual LF groups with
group A showed that only the mutation-carrying groups (B and C)
had longevities significantly greater than that of control group A
(Table 2B). We tested whether there was any difference between
the ages of biopsy donors from the control and LF groups by
comparing the group mean ages and found no significant differ-
ences (Kruskal-Wallis, P = 0.27: Mann-Whitney, A vs B to F
combined, P = 0.57; A vs mutation carriers B + C combined, P =
0.27). Then we compared the longevity of strains with the age of
the donors at the time of biopsy and the mean cell doubling times
(Table 3). Normal control strains showed a significant reduction in
longevity with increasing age of the donors, and a significant
reduction in mean population doubling time with increasing
longevity. However, although LF strains as a single group (B to F
combined) showed a significant reduction in longevity with
increasing age ofthe donors, this inverse correlation was not found
for the strains that carried mutations. Furthermore, no significant
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Table 4 Frequency of aneuploidy and chromosome aberrations
Groupa Strain PD Cells Percentage aneuploidc Aberrations per 100 cellsd
(% max)b scored
Total Hypo Hyper Dics Ace Ring DM Mar Other Total
A 85MA 30 (85) 50 0 0 0 0 0 0 0 0 6 6
33(94) 50 4 0 4 0 2 0 0 2 2 6
35 (100) 32 19 19 0 0 0 3 0 0 6 9
93MA 12 (19) 50 2 2 0 0 0 0 0 0 4 4
30(47) 20 50 50 0 0 0 0 0 0 0 0
44 (69) 50 14 14 0 0 0 0 0 0 2 2
54 (84) 50 100 95 5 58 8 0 6 6 6 84
61 (95) 10 100 60 40 130 20 0 140 230 0 520
105MA 29 (85) 45 2 0 2 0 2 0 0 0 2 4
34 (100) 50 14 4 10 2 0 2 0 0 0 4
89MA 21 (87) 50 6 6 0 0 0 0 0 0 0 0
23 (96) 32 16 16 0 2 0 2 0 0 4 8
162MA 26 (100) 12 0 0 0 0 0 0 0 0 0 0
B FH1 24 (44) 50 2 2 0 0 0 0 0 0 2 2
36 (65) 40 12 10 2 0 0 0 0 0 0 0
47 (85) 44 25 25 0 14 0 2 0 11 2 29
53 (96) 25 96 80 16 20 0 80 0 4 20 124
163MA 70 (100) 50 100 12 88 426 54 22 78 2 2 584
135MA 72 (97) 50 100 5 95 286 52 14 56 0 14 422
110MA 7 (13) 50 2 2 0 0 0 8 0 0 2 10
19 (36) 50 4 4 0 0 0 0 0 2 2 4
28(53) 50 36 8 28 0 0 0 0 4 2 6
47 (89) 25 88 36 52 96 16 16 12 4 16 160
124MA 20 (74) 50 0 0 0 0 0 0 0 0 12 12
22 (81) 50 20 20 0 8 6 2 0 0 0 16
23 (85) 50 48 36 12 36 6 0 6 4 6 58
25 (93) 50 76 72 4 66 24 18 12 0 0 120
C 138MA 30 (64) 50 6 4 2 8 0 2 0 0 0 10
45 (96) 17 89 11 78 106 39 0 89 44 11 289
21MA 40 (91) 50 28 10 18 4 0 0 0 0 0 4
109MA 12 (19) 50 2 2 0 0 0 0 0 0 0 0
33(52) 7 33 33 0 0 0 0 0 0 0 0
61 (96) 6 100 100 0 116 0 0 0 0 0 116
D 123MA 16 (94) 36 14 8 6 0 0 0 0 0 6 6
136MA 20 (83) 50 16 10 6 4 0 0 0 0 0 4
141MA 17 (100) 7 0 0 0 0 0 0 0 0 0 0
E 126MA 41 (76) 47 15 13 2 0 0 0 0 0 4 4
49 (92) 5 100 40 60 220 20 0 0 0 20 260
52 (99) 10 90 30 60 280 50 40 60 10 40 480
154MA 21 (60) 50 32 16 16 2 0 2 0 0 4 8
159MA 19 (100) 50 26 16 10 12 0 0 0 0 2 14
aGroups are defined in Table 2. bPopulation doubling at time of assay. cHypoploidy and hyperploidy cells with < or > 46 chromosomes. dDics, dicentrics; Ace,
acentric fragment; DM, double minute; Mar, marker chromosome; other, includes chromosome and chromatid breaks and gaps.
correlation was found in the LF strains between longevity and became aneuploid, even in the last 20% of their lifespan. Similar
mean doubling time. low levels of aneuploidy were also seen in three strains from non-
mutation-carrying blood relatives of heterozygotes (group D). An
Chromosome instability exceptional normal control strain was 93MA, all cells of which
were aneuploid during the last 20% oftheir lifespan. Initially, this
Metaphase preparations made at intervals during expansion of the was hypoploidy (range 40-45 chromosomes) but, close to senes-
cultures were analysed for numerical and structural aberrations cence, a substantial proportion of cells (40%) were hyperploid
(Table 4). Less than 20% of cells in four of five control strains (61-74 chromosomes). This strain behaved similarly to seven of
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Figure 2 Accumulation of structural chromosome aberrations with
increasing cell age. A, normal controls; B, mutation carriers
eight mutation-carrying LF strains (groups B + C) that showed a
high frequency (> 50% of cells) of aneuploidy before senescence.
These included 138MA, but 21MA (derived from an earlierbiopsy
obtained from the same donor) had only 28% aneuploid cells after
91% of their lifespan. Hypoploidy predominated in three strains
and hyperploidy in five strains. In strains from cancer-affected
individuals of families without mutations (group E), moderate
levels (26%, 32%) ofaneuploidy developed in two ofthree strains,
while the third strain, 126MA, behaved like mutation-carrying
strains and exhibited aneuploidy in most cells at late times.
In contrast to only one of five normal controls, seven of eight
mutation-carrying strains accumulated structural chromosome
aberrations in most cells during the second half of their lifespan
(Figure 2; P = 0.01, Fisher's exact test). The types of aberrations
observed are recorded in Table 4. As with aneuploidy, the excep-
tional strains were 93MA and 21MA. In control cells there was no
consistent pattern of aberrations, with the exception of 93MA, in
which the aberrations comprised dicentrics, acentric fragments,
double minutes and marker chromosomes, but no ring chromo-
somes. In mutation-carrying LF strains, 21MA was again excep-
tional in not showing the accumulation of aberrations that was
seen in 138MA. In mutation carriers, dicentrics were the most
common aberrations followed by acentric fragments and double
Table 5
strains
Loss of TP53 constitutional heterozygosity from mutation-carrying
Strain Family Population doubling TP53
(mutation) (% maximum) status
FH1 266 6.2 (11.2) m/+
(R248W) 20.1 (36.5) m/+
31.4 (57.1) m/+
43.1 (78.4) m/+
163MA 7.8 (11.1) m/+
25.2 (36.0) m/+
45.7 (65.3) ml+
65.2 (93.1) m/-
65.8 (94.0) m/-
138MA 83 16.9 (36.0) m/+
(R175H) 25.9 (55.1) m/+
43.5 (92.6) ml-
21MA 4.1 (9.3) m/+
16.5 (37.5) m/+
34.4 (78.2) ml+
36.0 (81.8) m/+
37.0 (84.0) m/-
135MA 6.3 (8.5) m/+
19.5 (26.4) m/+
33.7 (45.5) ml+
48.9 (66.1) m/+
68.7 (92.8) ml-
110MA 85 22.1 (41.7) m/+
(El80K) 35.4 (66.8) m/+
43.5 (82.1) m/-
50.1 (94.5) m/-
109MA 12.0 (18.7) m/+
16.3 (25.5) m/+
59.0 (92.2) m/-
160MA 7003 3.0 (17.6) m/+
(L344P) 4.1 (24.1) m/+
13.0 (76.5) m/-
minutes. Ring chromosomes, gaps and breaks were observed
frequently in some, but not all, of these strains, but marker chro-
mosomes were rare except in 138MA. Non-mutation carriers in LF
groups D, E and F generally behaved like the control group with
few aberrations being observed, except in 126MA, whose pattern
ofaberrations was like that ofthe mutation-carrying strains.
Genomic instability was also reflected in the loss of the wild-
type TP53 allele from late subcultures ofm/+ heterozygous strains
(Table 5). However, despite this, all of these strains underwent
senescence and none became immortal. A fibroblast strain derived
from the mesentery adjacent to a leiomyosarcoma of a
Li-Fraumeni patient with a codon 344 germline mutation
(161MA-F; Varley et al, 1996) was shown to have lost the wild-
type allele (m/-). This strain had a similar lifespan (19 PD) to that
of heterozygous cells derived from unaffected tissue from the
same patient (160MA, Table 1B) and neither of these strains, nor
163/29 (m/- clone of 163MA), produced tumours in nu/nu mice.
Resistance to ionizing radiation
The sensitivity to LDR ionizing radiation of 12 normal and 20 LF
strains was determinedby colony-forming assays afterexposure to0,
3 and 6 Gy (Figure 3). Three independent experiments were usually
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Figure 3 Survival of cells after exposure to LDR radiation. Colony-forming ability was measured after 3 Gy (A) and 6 Gy (B) in normal fibroblasts (group A)
and cells from LF groups B to F. Each point represents the mean survival of an individual strain. Bars are drawn arbitrarily at surviving fractions of 30% (3 Gy)
and 10% (6 Gy)
performed per cell strain using, as far as possible, early-passage
cultures in the first half of the cellular lifespan (Table 6). Statistical
analysis was performed on the mean survival values of each strain
(Table 7). The LF strains as a group (B to F combined) were signifi-
cantly more resistant (P = 0.032) than the control group at 3 Gy, but
the difference did not achieve statistical significance at 6 Gy
(P = 0.11). Comparison of individual groups with the control group
showed that resistance, now highly significant at both radiation doses
(P = 0.003), was confined to the mutation carriers (groups B and C).
In addition, we determined the survival of 2800T, previously
described as being resistant to HDR radiation (Bech-Hansen et al,
1981; Mirzayans et al, 1995), and three mutation-carrying strains
that had lost the wild-type allele (m/-), clone 163/29, 172MA and
the tumour-derived strain 161MA-F (Table 8). Taking two stan-
dard deviations of the mean of the control group as a limit of
significance, strain 2800T was significantly resistant at both radia-
tion doses and was the most resistant to LDR of all the strains
tested. By the same criterion, clone 163/29 was also resistant at
both doses, although this was borderline at 6 Gy, but 172MA and
161MA-F showed normal sensitivity. (We were unable to test the
sensitivity of the normal strain derived from the donor of 161MA-
F because of a combination of low plating efficiency and short
lifespan.) The same test was applied with approximately 95%
confidence limits to classify all the LF strains as either resistant or
normal in sensitivity (Table IB).
Finally, Mann-Whitney tests showed no significant effects of
either gender of donor or presence of cancer on radiation survival
in either the normal or the LF groups.
DISCUSSION
Eighteen fibroblast strains derived from skin biopsies of normal
volunteers were compared with cultures from members of eight
classical LFS families in which germline mutations had been iden-
tified, plus one LFL family with a germline mutation (family 85,
Table 1). In addition, we studied cells from three LFS families that
have no known mutation; genomic DNA from these families has
been sequenced through all exons, all exon/intron boundaries, 3'
and 5' untranslated regions and the promoter region without
finding any mutations (Varley et al, 1997b).
Genomic instability
We found that the most notable distinction between normal and LF
cells was the accumulation of aneuploidy and structural chromo-
some aberrations in LF cells with increasing PD. Within the last
20% of their lifespan, the majority of cells from seven of eight
mutation-carrier strains contained structural aberrations. In
contrast, only one of five normal strains behaved in this way. This
strain (93MA) was also exceptional in having a lifespan of 64 PD,
which was the longest of all the normal strains derived from adult
skin and was similar to that of H011, derived from an aborted
embryo. As the growth potential and chromosome instability of
93MA was similar to that of mutation-carrying cells, it seemed
possible that it too might have a TP53 mutation, perhaps acquired
during culture. However, against this hypothesis are the observa-
tions that, after exposure to ionizing radiation, 93MA and HOI1
show patterns of cell survival and permanent G, arrest character-
istic ofnormal cells (Sproston et al, 1996; Williams et al, 1996). To
be certain whether or not a mutation is present in 93MA, TP53
should be sequenced, but ethical constraints on sequencing DNA
from a normal individual have prevented us from doing this.
Our results show that aneuploidy is observed at earlier times,
and is thus a more sensitive indicator of genomic instability, than
are structural chromosome aberrations. However, strains that
develop high levels of aneuploidy also accumulate high levels of
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Table 6 Summary of clonal survival after low-dose-rate exposure
Family (mutation) Group Cell strain PD range (% max) Surviving fraction at Gy (%)
3 6
n Mean ± s.d. n Mean ± s.d.
Normal
Controls
266 (R248W)
222 (R248Q)
83 (R175H)
5580 (G245S)
A
B
83MA
84MA
85MA
86MA
89MA
120MA
156MA
157MA
162MA
169MA
170MA
176MA
FH1
163MA
131 MA
135MA
164MA
8-36
31-69
28-44
12-59
25-46
18-55
29-59
33-67
31-42
27-55
53-71
12-35
13-29
9-20
40-48
8-11
9-19
3
4
3
3
3
3
4
3
3
2
3
3
4
5
3
3
3
23.4 ± 3.9
29.0 ± 20.6
42.0 ± 7.8
6.8 ± 1.1
26.2 ± 18.8
28.0 ± 28.2
21.2 ± 5.8
9.5 ± 2.4
19.4 ± 4.2
11.4 ± 4.1
3.6 ± 2.7
19.2 ± 6.5
49.6 ± 9.0
43.0 ± 5.7
41.4 ± 6.7
44.9 ± 32.4
17.7 ± 2.1
3
4
3
4
3
3
4
3
3
2
3
3
4
5
3
3
3
6.0 ± 0.6
3.9 ± 3.1
16.0 ± 3.1
1.8 ± 0.2
9.2 ± 8.7
7.8 ± 7.7
6.2± 1.2
1.1 ±0.9
4.5± 1.9
3.5 ± 5.0
0.24 ± 0.18
6.0± 1.5
22.0 ± 7.9
19.8 ± 9.2
11.7 ± 3.2
21.0± 14.3
4.7 ± 2.3
3 57.7 ± 24.2
3 57.8 ± 12.2
3 39.2 ±7.2
3
3
3
3
4
10.3 ± 1.9
9.9 ± 4.0
21.3 ± 6.4
24.7 ± 14.3
37.5 ± 34.2
3 25.1 ± 10.5
2 45.6 ±4.9
3
3
3
3
3
40.6 ± 13.3
23.9 ± 1.6
8.5 ± 8.5
45.1 ± 17.9
13.5 ± 5.9
3 27.6 ± 5.5
3 22.7 ± 2.2
4 9.0±5.1
3
3
3
3
3
2.6± 1.8
0.9 ± 0.7
2.7± 1.1
2.3 ± 1.2
5.2 ± 3.1
3 9.9± 5.6
3 14.9±6.9
3
3
3
3
4
14.4 ± 5.0
5.6 ±4.8
4.0± 1.7
8.7 ± 7.1
3.3 ± 2.4
n, number of determinations.
structural aberrations. High instability is associated strongly with
heterozygosity at TP53 in families that have germline mutations,
although the time of onset and degree of aneuploidy is variable.
Whether hypo- or hyperploidy predominates may depend on the
type and timing of initial events that have a growth advantage.
Thus FHl and 163MA from family 266 (codon 248) showed
similar degrees of aneuploidy, but in the former hypoploidy
predominated whereas in the latter hyperploidy predominated.
Even cultures from the same individual behaved differently.
During the last 10% oftheir lifespan, 138MA and 21MA had 89%
and 28% aneuploidy and, although hyperploidy predominated in
both cultures, its contribution, relative to hypoploidy, was much
greater in 138MA (7.8:1) than in 21MA (1.8:1).
A further indication ofchromosome instability in LFcells was loss
of heterozygosity (LOH) at the TP53 locus in seven of eight strains
representing mutations in four different codons. We considered the
possibility that the genomic instability of the mutation-carrying
strains could be a consequence of the conversion from an m/+ to an
m/- genotype. Ofthe seven strains forwhich we have both LOH and
karyotype data, five (163MA, 138MA, 135MA, llOMA and
109MA) showed LOH at or just before the cell passage at which
mitoses were examined (Tables 4 and 5). The two exceptions were
FH1, forwhichLOH was not measured at late passages andtherefore
was non-informative, and 21MA, which showed LOH at 84%
maximum PD and showed increased aneuploidy, but not increased
chromosome aberrations, at 91% maximum PD. We conclude that in
most mutation-carrying strains there is a strong correlation between
loss ofthe wild-type TP53 allele and genomic instability. In support
ofthis conclusion, a chromosome count of30 metaphases ofthe m/-
strain 172MA (codon 337) atPD 5.7 (22% ofmaximum PD) resulted
in six hypoploid, four normal and 20 hyperploid cells (JMB and A
Spreadborough, unpublished data). Similarly, cells from p53 -/-
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83 (R175H) C
85 (E180K)
D
11-16
17-23
8-12
84 (+I+)
16 (+/+)
83 (+I+)
81 (+/+) E
21MA
138MA
109MA
66MA
123MA
125MA
136MA
141MA
79MA
81MA
126MA
146MA
154MA
80MA
130MA
18-46
35-47
47-60
12-29
35-59
18-24
22-25
17-25
38-54
23-57
88 (+/+)
80 (+/+)
81 (+1+)
88 (+1+)
F 31-54
33-50
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Table 7 Statistical analysis of survival data
Origin controls Normal Families with TP53mutation Families without TP53mutation
TP53 status +1+ +Im +I+ +I+
Clinical status and Normal Affected Not Blood Affected Not
family affected relative with affected
relationships of +/m LFS-type blood
case cancer relative
of
affected
case
Group designation A B C D E F
Number of strains in groupa 12 5 3 5 5 2
Mann-Whitney SF3:b 0.027 0.014 0.83 0.25 0.47
P-value of group
vs group A SF6: 0.015 0.021 0.14 0.14 0.72
Mann-Whitney A vs SF3 0.032
P-value for B-F SF6 0.11
differences A vs SF3 0.003
between groups B+C SF6 0.003
aStrains used are listed in Table 6. bSF3 and SF6, surviving fractions after 3 Gy and 6 Gy exposure respectively.
Table 8 LDR survival of four additional strains
Cell strain Surviving fraction at Gy (%)
3 6
n Mean + s.d. n Mean + s.d.
2800T 4 59.1 8.5 3 28.1 ±8.2
163/29 3 54.6 20.7 3 14.6 ± 6.9
172MA 3 32.2 ± 22.4 3 9.2 + 7.4
161 MA-F 4 29.9 4.6 4 8.6+ 0.9
Control Range 3.6-42.0 0.2-16.0
group A Range of 0-41.8 0-14.0
± 2 s.d.
mice show increased aneuploidy and stable chromosome aberrations
compared with cells from normal mice (Bouffler et al, 1995; Wang
et al, 1996).
Based on the timing of increase in growth rate coinciding with
loss of both the wild-type allele and the N-(phosphoacetyl)-L-
aspartate (PALA)-induced G, checkpoint, Tainsky et al (1995)
suggested that genomic instability is a property of early-passage
m/+ cells. In support of this hypothesis, introduction of mutant
TP53 under vector control into normal diploid fibroblasts induced
genomic instability. However, this was observed under conditions
of high levels of expression of p53 observable by Western blot
analysis (Liu et al, 1996), conditions that do not apply to LFS
fibroblasts. Our data argue against this hypothesis and support the
suggestion derived from cells of p53-deficient mice (Livingstone
et al, 1992; Harvey et al, 1993) that heterozygous cells have essen-
tially normal chromosome stability, but an increased probability of
converting to the m/- genotype that does show genomic instability.
Fibroblasts from LFS families without mutations also appear to
develop more aneuploidy than normal control cells, although to a
considerably lesser extent than the heterozygote strains and
sometimes unaccompanied by increased structural aberrations.
Although the strains studied in group E were all from cancer-
affected donors, the chromosome changes are probably not a result
of radio- or chemotherapy, because these were received 7 and 15
years before biopsy in cases 154MA and 159MA, respectively, and
only surgery was given in case 126MA, which showed the highest
levels ofaneuploidy and structural chromosomes within the group.
If the clinical features of LFS in these families result from altered
p53 expression, despite lack of any detected mutations in TP53,
then raised levels ofaneuploidy may be an indicator ofthis.
Longevity
Except for 93MA and HOI 1, the lifespans of normal control
fibroblasts ranged between 6 and 38 PD, compared with 17 and 74
PD for LF cells. There was thus a considerable overlap in
longevity between the two groups, although the mean values were
significantly different. Bischoff et al (1990) reported an increased
lifespan in strains carrying mutations, and our results confirm that
it is this group (B+C, Table 2) that has the longer lifespan.
However, there is a suggestion of heterogeneity within this group
giving a bimodal distribution, with four strains having 17-27 PD
falling within the normal range and eight strains showing longer
lifespan (44-74 PD). Loss of the wild-type TP53 allele (m/+ to
ml-) alone did not result in the immortalization ofLF cells.
As expected from earlier reports (Hayflick, 1965; Goldstein et
al, 1978; Allsopp et al, 1992), the longevity of normal fibroblasts
showed a relatively weak negative correlation with donor age, and
a similar result was obtained with LF cells (Table 3), but not for
the mutation-carrying strains, possibly because of the smaller
sample size. The mean population doubling time of early-passage
normal fibroblasts was inversely correlated with cellular lifespan,
so that cells with a short lifespan had relatively long doubling
times and vice versa. A similar, but non-significant correlation
held for mutation-carrying LF strains.
Radiation resistance
The third consequence of TP53 mutations is increased cellular
resistance to ionizing radiation, particularly when administered at
low dose rate (Sproston et al, 1996). A baseline for determining
relative resistance ofLF strains was established by determining the
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Fibroblast strain
TP53 status
Lifespan (PD)
Spontaneous
chromosome
aberrations
LDR survival
Permanent G,
arrest (%)
136MA
+2+
24
n
n
62
141MA
+1+
17
n
n
77
135MA
175/+
74
r
41
21MA/138MA
175/+
44 48
22MA
+2+
22
n
r r
39
Figure 4 End point correlations in family 83
survival of 12 normal control strains. The wide range ofsensitivity
observed was similar to that observed by others (Geara et al,
1992). Apart from the most resistant strain, 85MA, all other strains
gave survival values of < 30% at 3 Gy and < 10% at 6 Gy. Taking
these values as the arbitrary limits of normal sensitivity, the
majority of mutation-carrying strains were found to be resistant
(Figure 3). An exception was 164MA (codon 245) whose survival
at both doses fell within the normal range. A more stringent crite-
rion for resistance was to set the normal limits of sensitivity at +
two standard deviations ofthe mean values ofthe control group at
each dose (for example, see Table 8). When individual strains were
assessed against this standard, all LF strains not carrying muta-
tions had normal sensitivities (126MA was a borderline case), and
eight mutation-carrying strains from seven donors (21MA and
138MA were from the same donor) were resistant, but hetero-
zygous strains 131MA (codon 248), lO9MA (codon 180) and
164MA (codon 245) all had normal sensitivities. These results
illustrate that, although mutation-carrying strains as a group are
resistant to LDR radiation, the difference between normal and LF
strains is not large, and some LF strains are not significantly more
resistant than normal control strains. When it occurs, radiation
resistance in mutation-carrying strains would appear to be a prop-
erty of the heterozygous state, as experiments were carried out on
early-passage cells, before loss of the wild-type allele was
observed (Tables 5 and 6; Sproston et al, 1996). Furthermore, as
discussed below, radioresistance is not a universal feature of m/-
LFS fibroblasts.
The present series of experiments differed slightly from our
previous study (Sproston et al, 1996) in that feeder cells were not
used. Nevertheless, the results confirmed the relative sensitivities
ofthe strains used in common in the two studies. The earlier study
found FH1 (codon 248) to be the most resistant of four LF strains
with mutations in codons 175, 180, 220 and 248, which lie in the
domain of p53 that affects specific DNA binding and protein
conformation. The present data show similar high resistance in
163MA cells, from a sib ofthe donor ofFH1, and in the duplicated
strains 21MA and 138MA (codon 175). None of these strains are
as resistant as 2800T (codon 234), previously reported as being
resistant to HDR irradiation (Bech-Hansen et al, 1981). We also
determined the radiation response of 163/29, 172MA and 161MA-
F, mutation-carrying strains that have lost the wild-type allele.
Clone 163/29 was resistant, while 172MA and 161MA-F had
normal sensitivities. The mutations in 172MA (codon 337) and
161MA-F (codon 344) are in the carboxyterminal region that
contains domains affecting tetramerization, non-specific DNA
binding and possibly DNA damage recognition (Bristow et al,
1996). However, the karyotypes of all three strains are highly
abnormal (Varley et al, 1996; A Spreadborough, personal commu-
nication), which makes uncertain any correlation between muta-
tion and failure to confer resistance.
With strains derived from families with germline mutations, we
have now shown that, when resistance occurs, it is in the mutation-
carrying strains and not in the wild-type strains from these fami-
lies, thus supporting the idea that resistance is a consequence of
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the TP53 mutation. In families with no germline mutations in their
TP53 coding sequence, the presumption is that there is an unde-
tected mutation outside the regions of the gene studied (Varley et
al, 1997b), or in a gene regulating p53 activity, or in a gene whose
product can substitute for p53 in some, but perhaps not all, ways.
As the occurrence of specific types of cancer at young age (see
Introduction) is a characteristic feature ofthe syndrome, cells from
these families were classified according to whether or not their
donors had cancer, on the assumption that affected individuals
were most likely to be mutation carriers, although the possibility
was recognized that cancer in a specific individual may be a
sporadic event unrelated to p53. Radiation responses ofcells from
three such families were determined. Strains from family 88
fulfilled the prediction that cells from cancer-affected LF individ-
uals might show radiation resistance through a p53-like involve-
ment, as strain 126MA from a cancer-affected person was
marginally resistant, whereas 130MA from an unaffected blood
relative showed normal sensitivity. In family 81, marginal resis-
tance (resistant at 3 Gy, normal at 6 Gy) was seen in one of two
strains from cancer-affected individuals, but also in cells from an
unaffected individual who was biopsied at age 45 years. The
marginal resistance of 81MA is consistent with the extent of
permanent G arrest in 81MA seen in a recent study that demon-
strated that the radiation resistance ofLF strains is inversely corre-
lated with the fraction ofcells that are able to progress through the
cell cycle when irradiated in G, (Williams et al, 1996). In the third
family, family 80, two strains from affected individuals both
showed normal sensitivity. Family 80 is a large family, the most
dramatic cases of which show linkage to a BRCA2 haplotype (J
Heighway and G White, personal communication). Thus, cellular
radiation resistance is not a consistent characteristic of LFS fami-
lies without TP53 mutations and, even when it occurs, it is difficult
to demonstrate.
Mechanistic interpretation of the data
Because of the multiple effects of p53 on cell growth and survival
(recently reviewed by Ko and Prives, 1996), it is not possible at
present to be precise about the mechanisms causing the effects we
have observed. However, the following scenario, although
simplistic, could account for most of the observed phenotypes.
DNA strand breaks occur spontaneously as a result of cellular
metabolism and through damaging agents such as ionizing radia-
tion. p53 detects and is induced by the presence of double-strand
DNA breaks (Nelson and Kastan, 1994) and at high concentrations
causes transactivation of the cyclin-dependent kinase inhibitor
p21, which is strongly implicated in permanent G, arrest (Di
Leonardo et al, 1994; Williams et al, 1997) and senescence (Noda
et al, 1994). We assume that p53 monitors the genome for DNA
breaks (Lane, 1992) and is involved in their repair through interac-
tions with repair proteins. As cells age, the fidelity of replication
and repair may breakdown and greater numbers of DNA breaks
may accumulate, resulting in an increased probability of chromo-
some aberrations and the transactivation of p21, leading to senes-
cence. Abrogation of these effects by mutation could lead to
increased longevity, decreased permanent G, arrest and may allow
enhanced survival of genetically damaged cells after genotoxic
insult (Williams et al, 1997).
The consequences of TP53 mutation are best illustrated by
family 83, from whom the greatest number of cell strains was
available (Figure 4). In this family, a de novo TP53 mutation in
codon 175 occurred in generation II and was transmitted to the son
in generation III. The presence of the mutation resulted in
increased fibroblast lifespan, increased frequency of spontaneous
structural chromosome aberrations and increased resistance asso-
ciated with decreased permanent G, arrest in response to exposure
to ionizing radiation.
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